Last week, the FDA released the updated Guidance on Post-approval Pregnancy Safety Studies (May 2026).
Since pregnant individuals are generally excluded from pre-approval clinical trials, most medicinal products enter the market with limited or no pregnancy safety data. Post-marketing surveillance therefore becomes crucial to inform clinical practice and labelling updates.
This guidance marks a pivotal step in strengthening how we generate and interpret evidence on medicine use before, during, and after pregnancy:
- Pregnancy safety evidence cannot be an afterthought
- Fit-for-purpose real-world data and robust methodology are critical
- A portfolio of complementary studies is often needed
For pharma and health tech innovators, this shifts expectations toward:
– Early strategic planning for pregnancy safety commitment
– Rigorous confounding control and transparent analytic frameworks
– Hybrid evidence models integrating complementary real-world data
As regulators continue to incorporate real-world evidence into safety and labelling decisions, strategic foresight and methodological excellence will become critical.
And we are here to help.
Ciencia Research has experience in delivering high-quality maternal health and post-approval safety studies. Come talk to us and learn about our experiences and discuss how we can support your evidence needs.
How are you planning your pregnancy safety evidence strategy?
#PregnancyCare
#MaternalHealth
#DrugSafety
#Pharmacovigilance
#FDA
